Boehringer Ingelheim Venture Fund is the corporate venture capital arm of Boehringer Ingelheim. The firm invests in companies operating in the oncology, biologics, genetherapy, therapeutics and healthcare sectors. It is based in Ingelheim am Rhein, Germany and was founded in 2010.
Endeavour Vision is a growth investor in exceptional private medtech companies, and an ideal partner for medtech entrepreneurs. Headquartered in Geneva, Switzerland with a presence in the United States, the Endeavour Vision team comprises experienced investors, seasoned entrepreneurs and medtech specialists, all committed to helping entrepreneurs grow and develop thriving businesses. Endeavour’s latest $275 million fund is fully dedicated to investing in European and US medtech companies that seek worldwide growth and aim to improve the quality and cost of care for patients across the globe.
Based in Saratoga. Invests in Games, Mobile, Consumer Internet, Information Technology, Nanotechnology, Communications Infrastructure, Software, Security, Consumers, Content, Financial Services, Medical, Health Care Information Technology, Small and Medium Businesses, Information Services, Bridging Online and Offline, Fashion, Location Based Services, Social Media, Advertising, SaaS, Music, Enterprise Software, Analytics, 3D Printing, 3D Technology, 3D, Marketplaces, ECommerce, Healthcare, B2B, Big Data, Mobile Commerce, Entertainment, Education